Epigenome-wide meta-analysis identifies DNA methylation biomarkers associated with diabetic kidney disease

Nat Commun. 2022 Dec 22;13(1):7891. doi: 10.1038/s41467-022-34963-6.


Type 1 diabetes affects over nine million individuals globally, with approximately 40% developing diabetic kidney disease. Emerging evidence suggests that epigenetic alterations, such as DNA methylation, are involved in diabetic kidney disease. Here we assess differences in blood-derived genome-wide DNA methylation associated with diabetic kidney disease in 1304 carefully characterised individuals with type 1 diabetes and known renal status from two cohorts in the United Kingdom-Republic of Ireland and Finland. In the meta-analysis, we identify 32 differentially methylated CpGs in diabetic kidney disease in type 1 diabetes, 18 of which are located within genes differentially expressed in kidneys or correlated with pathological traits in diabetic kidney disease. We show that methylation at 21 of the 32 CpGs predict the development of kidney failure, extending the knowledge and potentially identifying individuals at greater risk for diabetic kidney disease in type 1 diabetes.

Publication types

  • Meta-Analysis
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • CpG Islands
  • DNA
  • DNA Methylation / genetics
  • Diabetes Mellitus, Type 1* / complications
  • Diabetes Mellitus, Type 1* / genetics
  • Diabetic Nephropathies* / genetics
  • Epigenesis, Genetic
  • Epigenome
  • Genome-Wide Association Study
  • Humans


  • Biomarkers
  • DNA